Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases

E-ISSN： 2212-3873|6|4|373-381

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.6, Iss.4, 2006-12, pp. : 373-381

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Interleukin-6 Therapy for Crohn's Disease

Current Pharmaceutical Design, Vol. 9, Iss. 4, 2003-02 ,pp. : 295-305

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody

By Smith Deborah A.

Clinical Pharmacokinetics, Vol. 50, Iss. 4, 2011-04 ,pp. : 215-227

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 2, 2016-03 ,pp. : 102-108

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mepolizumab: 240563, Anti-IL-5 Monoclonal Antibody - GlaxoSmithKline, Anti-Interleukin-5 Monoclonal Antibody - GlaxoSmithKline, SB 240563

By Adis International Limited

Drugs in R&D, Vol. 9, Iss. 2, 2008-01 ,pp. : 125-130

Adis International

Access to resources Recommend Favorite

Anti-Interleukin-2 Receptor Antibodies for the Prevention of Rejection in Pediatric Renal Transplant Patients: Current Status

By Swiatecka-Urban A.

Pediatric Drugs, Vol. 5, Iss. 10, 2003-01 ,pp. : 699-716

Adis International

Access to resources Recommend Favorite